Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P30536 (
PBS
)
9,886
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Light and electron microscopy were employed for evaluation of hepatic biopsies (9 puncture and 3 operative) to study morphologic changes in small bile ducts and lobular parenchyma in primary biliary cirrhosis (PBC). Altogether 12 female patients with PBC stage I and II and aged 36-59 were examined. Immune cytolysis of biliary epithelium indicative of delayed-type hypersensitivity is shown to underlie destructive cholangitis. The appearance of the canals between hepatocytes of the hepatic plate which connect biliary capillaries with perisinusoidal space evidence for impairment of hepatic lobular parenchyma. Cholemia and absence of hepatic
cholestasis
in
PBS
stage I may be due to bile capillary drainage into the hepatic sidusoids along these newly originated intercellular canals.
...
PMID:[Morphogenesis of primary biliary liver cirrhosis]. 337 95
Heptral (S-adenosine-L-methionine) was given to 32 patients with chronic diffuse diseases of the liver and intrahepatic
cholestasis
. 16 of them had primary biliary cirrhosis (PBC). Phase I of the treatment lasted 16 days when the drug was injected intravenously in a dose 800 mg/day. It was followed by phase 2--1600 mg/day taken for 16 days. A response was registered in the majority of patients. They had relieved symptoms of asthenia, skin pruritus, jaundice. The patients with liver cirrhosis and chronic hepatitis exhibited a statistically significant fall in ALT, AST and GGTP.
PBS
patients showed insignificant lowering of cholesterol, bilirubin. No resistance was noted in repeated courses. Heptral tolerance was satisfactory.
...
PMID:[Clinical trial of heptral in patients with chronic diffuse liver disease with intrahepatic cholestasis syndrome]. 986 18